Today, in the 72nd ASRM Scientific Congress, which is taking place over the course of several days in Salt Lake City (Utah, USA), Prof. Carlos Simón, Scientific Director of IGENOMIX, presented a prospective and randomized study titled Prospective, randomized study of the endometrial receptivity analysis (ERA) test in the infertility work-up to guide personalized embryo transfer versus fresh transfer or deferred embryo transfer.
The study serves as proof that the ERA test, to this date used only on patients encountering difficulties, offers a significant improvement to the overall pregnancy rate, which stands at 85% in personalized transfers according to test results.
Furthermore, it has been selected Prize Paper by the Society for Reproductive Endocrinology and Infertility in this year’s Annual Meeting.
The ERA test (Endometrial Receptivity Analysis) works by analyzing the expression of 238 genes in the endometrium, providing insight into its receptivity or lack thereof when embryo transfer takes place. In recent years, it has enhanced the reproductive prognosis of many patients by offering a personalized window of implantation.
This test, patented by Igenomix in 2012, determines the optimal moment for embryo transfer on a case-by-case basis, fully incorporating personalized treatment into the fertility clinic.